Combination therapy with three drug regimens for human immunodeficiency virus (HIV) infection significantly suppresses the viral replication. However, this therapeutic impact is restricted by adverse drug events and response in terms of short and long term efficacy. There are multiple factors involved in different responses to antiretrovirals (ARVs) such as age, body weight, disease status, diet and heredity. Pharmacogenomics deals with individual genetic make-up and its role in drug efficacy and toxicity. In depth genetic research has provided evidence to predict the risk of developing certain toxicities for which personalized screening and surveillance protocols may be developed to prevent side effects. Here we describe the use of pharmacogenomics for optimal use of HAART (highly active antiretroviral therapy).

Key words HAART - HIV- NNRTI - NRTI - personalized medicine - pharmacogenomics

Introduction

Introduction of highly active antiretroviral therapy (HAART) has drastically reduced mortality associated with HIV infection, but variability in efficacy and toxicity is challenging. The advances in molecular biology has changed pharmacogenetics to a great extent to develop pharmacogenomics. Host genetic factors are accountable for the variability in antiretroviral (ARV) response along with sex, body mass index, heredity and disease progression. Sometimes genetic variability is solely responsible for these variations. A single-nucleotide change is a DNA sequence variation occurring commonly within a population at the same locus of the gene which may alter functioning of the protein product extensively. Single-nucleotide change hardly affects functioning of the protein produced by that gene, but some changes affect functioning. Single nucleotide polymorphisms (SNPs) are significant with respect to genes of drug metabolic pathway including enzymes, drug carrier proteins involved in pharmacokinetics and disease progression. The influence of SNPs on personal responses to pharmacotherapy is complicated. Genetic variations in pathways of drug absorption, disposition, metabolism and excretion (ADME) contribute to inter-patient differences. Therefore, genes encoding for transport proteins, drug metabolizing enzymes or nuclear receptors have been the main targets of HIV pharmacogenomic studies. So far, numerous associations of SNPs with susceptibility to ARV drug adverse reactions or risks of virological failure have been reported. This review focuses on some important aspects of pharmacogenomics to maximize efficacy and minimize toxic effects of HAART.
Pharmacogenomics

Combination antiretroviral therapy (cART) for HIV - HAART or cART has improved the prognosis of HIV infection close to normal life expectancy. With HAART, different combinations of antiretroviral drugs are available for untreated and treated individuals. There are six categories of drug regimens available as follows: (1) Nucleoside reverse transcriptase inhibitors (NRTIs), (2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (3) Protease inhibitors (PIs), (4) Integrase inhibitors (IIs), (5) Fusion inhibitors (FIs), and (6) Chemokine receptor antagonists. The choice of treatment is mainly influenced by HIV disease stage, co-morbidities, co-medication with potential drug-drug interactions, pregnancy or pregnancy potential, expected cART toxicity, and results of genotypic resistance testing and synergism/antagonism of the combination on HIV virus life cycle.

Table I gives summary of some key reported genetic variants for HAART. Table II provides information on pharmacogenetics of adverse reactions due to HAART.

1. Nucleoside reverse transcriptase inhibitors (NRTIs):
NRTI is a nucleoside analogue antiretroviral drug and its chemical structure constitutes a modified version of a natural nucleoside. These inhibit viral replication of retroviruses by stopping extension of oligomer due to absence of 3’ hydroxyl group essential for addition of incoming new nucleotide. This prevents further synthesis of viral nucleic acid by interfering with the reverse transcriptase enzyme (Fig. 1). These drugs get activated on endocytosis after phosphorylation to form active triphosphate compound (pro-drugs). The known drug toxicities are linked with lipid metabolism, liver steatosis and lactic acidosis. Additional evidence relates NRTI drugs to disruption of mitochondrial function, oxidative stress and peripheral neuropathy.

Zidovudine (ZDV) (Azidothymidine, AZT) - Thymidine analogue - Zidovudine is a nucleoside analogue antiretroviral drug and its chemical structure constitutes a modifiedversion of a natural nucleoside. These inhibit viral replication of retroviruses by stopping extension of oligomer due to absence of 3’ hydroxyl group essential for addition of incoming new nucleotide. This prevents further synthesis of viral nucleic acid by interfering with the reverse transcriptase enzyme. These drugs get activated on endocytosis after phosphorylation to form active triphosphate compound (pro-drugs). The known drug toxicities are linked with lipid metabolism, liver steatosis and lactic acidosis. Additional evidence relates NRTI drugs to disruption of mitochondrial function, oxidative stress and peripheral neuropathy.

As compared to 71 per cent cases on TDF only because ZDV had to be withdrawn in 11 per cent (vs 5%) of the cases after drug adversities in 14 wk. Observed ZDV related toxicities include drop in haemoglobin level and neutrophil count, and nausea due to gastrointestinal disturbances within a few weeks on initiation of the trial. Also, fat deposition in upper and lower extremities was significantly reduced on ZDV treatment.

A pharmacogenetic study has reported higher levels of ZDV-triphosphates (up to 49%) in HIV cases heterozygotes for ABCC4 G3724A on ZDV treatment as compared to wild type GG homozygote. Another variant ABCB1 GT or TT has shown significantly reduced levels of HIV viral load than that in individuals having wild type GG genotype. Kwara et al. have shown 196 per cent oral drug clearance associated with UGT2B7*1c carriers on ZDV therapy when compared to non carriers. These studies emphasize on extensive analysis using large cohorts for understanding potential role of pharmacogenomic factors in ZDV pharmacokinetics and pharmacodynamics.

Stavudine (d4T) - Thymidine analogue - Stavudine (2’,3’-didehydro-2’,3’-dideoxythymidine) was made available for patients showing virological failure or intolerance to ZDV after its approval in May 1996.
After one year, it became the preferred drug for ART. But it was found to be associated with susceptibility to body fat side effects. Therefore, in 2009, the World Health Organization (WHO) restricted its use due to long-term, irreversible side effects.

Lamivudine (3TC) - Cytidine analogue - Lamivudine (2’,3’-dideoxy-3’-thiacytidine) is another nucleotide analogue used in combination therapy for delaying developments of acquired immunodeficiency syndrome (AIDS) and hence, avoiding disease related complications or cancer. Higher intracellular concentrations of 3TC-triphosphate have been reported to be associated with multidrug resistance protein 4 (MRP4) T4131G change and MRP2 polymorphism.

Tenofovir disoproxil fumarate (TDF) - Adenosine analogue - Tenofovir, one of the most effective and commonly prescribed antiretroviral drugs belongs to a class of nucleotide reverse transcriptase inhibitors (NtRTIs). Nucleotide analogues have phosphate group in addition to pentose and nucleic base of nucleoside. Unlike nucleoside analogues, NtRTIs are chemically preactivated and thus require less processing in the body. A single G>A substitution at 1249 nucleotide
| Class | Drug  | Gene       | Polymorphisms                      | Clinical impact (Efficacy/Toxicity) | Ref. |
|-------|-------|------------|-----------------------------------|-------------------------------------|------|
| NRTIs | ZDV   | ABCC4      | A1203A                            | Higher intracellular ZDV - TP        | 5    |
|       |       | UGT2B7*1c  | c.735A>G                          | 196% Higher ZDV oral clearance      | 5    |
|       |       | ABCB1      | G2677T                            | Greater reduction of HIV RNA        | 5    |
|       | d4T   | POLG       | R964C and E1143G                  |                                     | 6    |
|       | 3TC   | ABCC4      | T4131G                            | Higher intracellular 3TC - TP        | 6    |
|       | ABC   | HLA-B HLA-B*57:01 | NA  | Toxicity - HSR                    | 7,8  |
|       |       | HLA complex P5 | 335T>G  | Toxicity - HSR                    | 9-12 |
| TFV (NtRTI) | ABCC2 | CATC Haplotype (-24, 1249, 3563, 3972) 24CC |  | Toxicity - KTD                     | 13,14|
| NNRTI | EFV   | CYP2B6     | 516C>T, 785A>G and 983T>C         | Higher plasma levels/CNS adverse effects | 16-24|
|       |       | ABCB1      | 3435C>T                           | Possible influence in plasma EFV levels | 25-28|
|       | NVP   | CYP2B6     | 516C>T and 983T>C                 | Higher plasma levels                | 17,19, 29-31|
|       |       | ABCB1      | 3435C>T                           | -                                  | 32,33|
|       |       | HLA-DR     | HLA- DRB1*0101                    | Toxicity - HSR                      | 34,35|
|       |       | HLA-C      | HLA-Cw*8                          | Toxicity - HSR                      | 36   |
|       |       | HLA-B      | HLA-B3505                         | Toxicity - skin rash                | 37   |
| PIs   | ATV   | UGT1A1*28  | *28                               | Toxicity - Gilbert’s syndrome and Higher levels of bilirubin | 38-40|
|       |       | ABCB1      | 3435C>T and 2677G>T              | Lower plasma levels                 | 39, 41|
|       |       | NR1I2      | 63396C>T                         | Lower plasma levels                 | 42   |
|       | RTV   | ABCA1, APOA5, APOC3, APOE, CETP    | -                                | -                                  | 6    |
|       |       | IDV        | UGT1A1*28                          | -                                  | 6    |
|       |       | CYP3A4*1B / CYP3A5*1               | -                                | -                                  | 6    |
| II    | RAL   | ABCB1      | 3435C>T                           | Allele T is associated with lower RAL plasma exposure | 43   |
| EI    | MVC   | CCR5       | Δ32                               |                                     | 6    |

ZDV, zidovudine; d4T, stavudine; 3TC, lamivudine; ABC, abacavir; TFV, tenofovir; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; RTV, ritonavir; IDV, indinavir; RAL, raltegravir; MVC, maraviroc; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor; EI, entry inhibitor; HSR, hypersensitivity; KTD, kidney tubular dysfunction; DP, diphosphate; NA, not applicable; TP, triphosphate
Table II. Pharmacogenetics of adverse reactions due to HAART

| Regimen               | Pharmacogenetics                                      | Side effects                                      |
|-----------------------|-------------------------------------------------------|---------------------------------------------------|
| **NNRTI – based regimen** |                                                       | (i) Low genetic barrier to resistance             |
| 2 NRTIs + 1 NNRTI     | ZDV 3724G>A, c.735A>G, G2677T d4T R964C, E1143G 3TC T4131G  |
| (1) ZDV/d4T + 3TC + NVP | TFV CATC Haplotype (-24, 1249, 3563, 3972) 24CC, 3463A>G, -669C>T |
| (2) ZDV/d4T + 3TC + EFV | EFV 516C>T, 785A>G, 983T>C, 3435C>T NVP HLA-DRB1*0101, HLA-Cw*8 and  |
| (3) TFV + 3TC + NVP/EFV | NVP HLA-B3505                                        |
| **Triple NRTI – based regimen** |                                                       | (ii) Cross-resistance among NNRTIs                |
| (1) AZT + 3TC + ABC   | ZDV 3724G>A, c.735A>G, G2677T d4T R964C, E1143G 3TC T4131G  |
| (2) d4T + 3TC + ABC   | ABC 335T>G                                           |
| **PI - based regimen** |                                                       | (iii) Potential for hepatic and skin toxicity     |
| (1) 2 NRTIs + ATV/r or LPV/r | ZDV 3724G>A, c.735A>G, G2677T d4T R964C, E1143G 3TC T4131G  |
| (2) 2 NRTIs + NFV     | ABC 335T>G                                           |
| (i) Higher pill burden |                                                       | (iv) Potential teratogenicity (EFV)               |
| (ii) Gastrointestinal side effects common |                                                       | (v) High potential for interactions with other medications |
| (iii) Metabolic complications common |                                                       |                                                  |
| (iv) Refrigeration requirements for some PI drug (RTV, LPV/r) |                                                       |                                                  |
| (v) High chances for interactions with other medications |                                                       |                                                  |

**Source**: 4, 44

of ATP-binding cassette, sub-family C, member 2 (ABCC2) gene is reportedly linked with TDF adverse reaction causing renal tubulopathy\(^6\). Interestingly, TDF is not a substrate for MRP2, but for MRP4\(^15\). More recently, a naïve association between ABCC4 3463A>G genotype and renal toxicity has been reported showing tenofovir concentrations 35 per cent higher in carriers of the 3463G variant\(^44\).

Abacavir (ABC) - Guanosine analogue - Hypersensitivity to ABC occurs in about five per cent of HIV infected patients usually by the second week of ABC treatment. In some cases, hypersensitivity reaction is seen by six weeks\(^56\). A polymorphism in HLA gene HLA-B*5701 needs to be screens prior to initiation of ABC treatment to avoid hypersensitivity reaction. An inexpensive laboratory test is available to detect this gene\(^57\). HLA B57 frequency is 5-20 per cent in India\(^58\). An Indian study\(^58\) demonstrated that HLA B17 frequency in HIV patients on antiretroviral therapy was due to the different composite ethnic groups studied. The testing for HLA B17 antigen along with HLA B*5701 allele subtype can be used as pharmacogenetic testing to prevent abacavir hypersensitivity reaction among Indian patients\(^58\). This testing is now mandatory in many countries before prescribing abacavir\(^9\). HCP5 335 T>G polymorphism in P5 gene of HLA is preferred.

![Fig. 1. Mode of action of nucleoside reverse transcriptase inhibitor (NRTI). On incorporation of NRTI the chain is terminated. ssDNA, single strand DNA.](image-url)
SNP marker over HLA B*5701 for ABC sensitivity due to simplicity and economicity.10-12

2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Non-nucleosides are directly active drugs as against prodrug NRTIs. These prevent HIV replication by targeting the enzyme reverse transcriptase, binding to a site near to but different from the active site for substrate. It decreases DNA synthesis drastically (Fig. 2). ADME pathways genes are studied extensively focusing on CYP450 enzyme. Detoxification of NNRTI takes place in liver by CYP450 enzyme. SNPs associated with these isoenzymes play crucial role in inter-individual differences in metabolism and disposition of NNRTIs. Polymorphisms result in decreased expression of enzymes and their activity in liver microsomes. As a result, there is considerable inter-individual variability in NNRTI ADME. Also, genes encoding drug transporters and HLA are considered in the pharmacogenetic studies of NNRTI. SNPs in MDR1 gene, which encodes for P-glycoprotein (P-gp) affect oral absorption and desorption of NNRTIs. P-glycoprotein acts as a NNRTI carrier. The association between variants of MDR1 gene and NNRTI plasma concentrations has been studied comprehensively.

Nevirapine (NVP) - In 1997, NVP was approved as NNRTI. In developing countries, it is the preferred first line drug in combination with two NRTIs due to its efficacy, moderate price and adjustable dosage. NVP causes elevation of liver enzymes which may occasionally be severe. About 15-20 per cent patients experience rash and NVP needs to be withdrawn in about 7 per cent of them. NVP-induced rashes were reported in 2.14 per cent of HIV positive individuals from India. It is noteworthy that liver damage may appear after many months. NVP induced hypersensitivity is associated with HLA-DRB1 allele and MDR1 gene polymorphism. The polymorphism ABCB1-3435C>T is linked with a decreased risk of hepatotoxicity in patients receiving NVP. NVP plasma concentration is affected by G516T and 983 T>C substitutions in CYP2B6 gene. Also, significantly higher NVP plasma levels are reported in black patients heterozygous for T983C SNP. Although sex, age, body mass index, habits, habitat and pathological liver condition are major criteria in influencing pharmacokinetics of NVP, but in most of the studies only body weight is included.

Efavirenz (EFV) - EFV is the first line drug for untreated HIV infected cases. EFV shows a narrow therapeutic range and there is a potential risk of high level of therapeutic concentrations that are related with virological failure or neurological manifestations. It is metabolized by CYP2B6 in liver. The G516T SNP in CYP2B6 (CYP2B6*6) is reported to have a major impact on the pharmacokinetics and pharmacodynamics of EFV. Black patients are predisposed to the CNS effects due to high prevalence of the genotype CYP2B6 - 516TT. Also, there is SNP variability due to 785 A>G, 983 T>C, 593 T>C and 1132 C>T substitutions in CYP2B6 rendering slow metabolism of EFV. This affects its pharmacokinetics with increased drug levels, which result in CNS events or virological failure, necessitating CYP2B6 allele genotyping. Efavirenz disrupts sleep architecture.

3. Protease inhibitors (PIs): HIV hijacks host genetic codeoninvadingCD4cellandutilizeshostcellmachinery for its replication. The viral gag-pol polyprotein is excised into active protein particles of newly formed virus by viral protease, a molecular scissor. This step is inhibited by blocking the protease enzyme using PIs by preventing a proteolytic splicing and results into non-infectious virus particles (Fig. 3). Toxic effects of PIs include lipodystrophy, dyslipidaemia, tolerability problems and gastrointestinal disturbances. Often drug interactions are substantiated due to PIs. PIs are mostly metabolized by CYP3A4. PIs act both as inhibitors of and substrate for CYP3A4. CYP3A4 also metabolizes both simvastatin and lovastatin. When PIs act as inhibitor of CYP3A4, the levels of simvastatin

Fig. 2. Mode of action of non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block enzyme activity by binding directly to reverse transcriptase (RT) enzyme.
and lovastatin may increase drastically\textsuperscript{69,70}. This in turn increases the risk of toxicity of liver and skeletal muscle\textsuperscript{71}.

Ritonavir (RTV) - Ritonavir is included in combinational regimen because it blocks host enzymes involved in metabolism of PIs. It is the most powerful of all the PIs even in low doses. The primary role of RTV in boosted PI regimens is to improve the pharmacokinetics of the second PI. RTV inhibits host enzymes of drug metabolic pathways causing their levels to rise in bloodstream, and increasing efficacy of other PIs with reduced dose and frequency rendering them more compliant. It also blocks its own metabolism by inhibiting cytochrome P450\textsuperscript{72}. Liver enzymes metabolize protease inhibitors only when their activity is modified. All PIs decrease hepatic enzyme activity. These increase cholesterol and triglycerides levels, cause abnormal fat deposition in various parts of the body, and diabetes. These can be associated with polymorphisms of genes like ATP-binding cassette transporter A1 (\textit{ABCA1}), apolipoprotein A5 (\textit{APOA5}), apo lipoprotein C3 (\textit{APOC3}), apo lipoprotein E (\textit{APOE}), and cholesterol ester transfer protein (\textit{CETP})\textsuperscript{73}. APOE and APOC3 variant alleles are associated with increased risk of hypertriglyceridaemia associated with RTV\textsuperscript{74,75}.

Atazanavir (ATV) - In March 2004, ATV arrived in market as daily prescription in single dose. Increased lipid levels associated with this drug make oneself susceptible to cardiovascular event\textsuperscript{74}. Fifty per cent of cases on ATV show rise in bilirubin levels and above one third have grade 3-4. This is also true for lipodystrophy\textsuperscript{75,76}. Some patients even develop jaundice as hepatic conjugation is hampered due to a mechanism similar to Gilbert’s Syndrome. A genetic predisposition is identified\textsuperscript{77}. This side effect is provoked by competitive inhibition of UDP glucuronosyl transferase 1 family polypeptide A1 (\textit{UGT1A1}), the microsomal enzyme causing glucuronidation, which allows bilirubin excretion. Inconsequential rise needs withdrawal of ATV in a few patients due to overt jaundice\textsuperscript{78}. A previous Indian study has reported increased prevalence of of (TA)\textsuperscript{7}/(TA)\textsuperscript{7} genotype in neonates (allele frequency 0.366)\textsuperscript{79}. UGT1A1 promoter variant is associated with hyperbilirubinaemia\textsuperscript{79}. The presence of SNP UGT1A1*28 is strongly associated with the occurrence of jaundice because of decreased enzyme activity\textsuperscript{52,57,80}.

Indinavir (IDV) - Highly penetrating IDV reaches genital compartments and CNS, but it is not preferred nowadays\textsuperscript{39}. This medicine needs to be used with caution in India due to presence of extensive ‘renal stone belt’ to avoid the risk of nephrolithiasis\textsuperscript{81,82}.

4. Integrase inhibitors (IIs): HIV integrase is an important enzyme in its replication through integrating viral DNA with host genome\textsuperscript{83}. Integrase inhibitor is a desirable anti-HIV drug as integrase enzyme is absent in human cells; its selective inhibition without side effects is possible (Fig. 4).

Raltegravir (RAL) - Raltegravir is an aphythrydine carboxamide derivative that inhibits integrase. Integrase catalyses the step-wise process of integrating HIV-1
DNA into the host genome. In the process, assembly of integrase with viral DNA forms stable pre-integration complex, which follows endonucleolytic processing of the viral DNA ends, and joining of the viral and host DNAs. Covalent bonding takes place in 5' phosphate groups exposed on nicking cellular DNA strands of host and viral DNA to produce provirus. RAL does not allow pre-integration complex to bind to host DNA. It prevents replication of HIV-2 and acts against R5 and X4 tropic viruses. RAL is a substrate of the P-gp, and consequently, polymorphisms in transport proteins may explain the large intra- and inter-individual variations of RAL exposure. A recent study in Spanish HIV RAL-cohort reported that the polymorphism at *ABCB1*-3435C>T was associated with RAL concentrations. Patients carrying CT or TT genotypes displayed lower median RAL concentrations than those with the CC genotype. Although pharmacokinetic/pharmacodynamics (PK/PD) analyses do not suggest a threshold RAL concentration associated with reduced efficacy, patients carrying CT/TT genotypes at the P-gp gene might be more prone to virological failure. The *UGT1A1*28/*28 genotype is associated with higher RAL plasma concentrations compared to that of *UGT1A1*1/*1 genotype.

5. Fusion inhibitors (FI): Thirty-six amino acids long peptide of the FI enfuvirtide (T-20) is similar to a portion of gp41, necessary for binding to heptad repeat 1 (HR1). It interferes with HR1 and HR2 interaction and thereby, inhibiting the conformational change crucial for viral fusion to CD4 cells. Decreased efficacy of T-20 is associated with a single amino acid substitution in HR1. The drug is efficacious with hardly any side effects. However, its high cost, intolerance on long term use, complex mode of administration and limited pharmacokinetic properties are the limiting factors, and in future, studies should focus on these aspect to enhance its clinical advantage.

6. Entry inhibitors (EI): HIV enters human body through fusion of viral envelope proteins with binding domain on host CD4+ (cluster of differentiation 4) cell. Els interfere with this fusion step and stop virus from entering into the cell, thereby restricting HIV from infecting a cell and multiplying. Theoretically inhibitors can interfere with every step of HIV entry into the host cell. Els mainly target either the viral envelope glycoprotein gp120 or gp41 or the C-C chemokine receptor CCR5 or CXCR4 receptors on a CD4 cell surface. Intracellular HIV inhibition is not possible by EIs as against other drug classes.

Maraviroc (MVC) - Maraviroc belongs to entry inhibitors called as CCR5 receptor antagonist. HIV makes entry into host cell using a CCR5 receptor present on CD4+ immune cells. MVC prevents entry of HIV by inhibiting its fusion with the CCR5 receptors (Fig. 5). It allosterically binds to CCR5 by inducing conformational changes within CCR5 and hence, inhibiting its binding to viral gp120. It acts against CCR5 tropic viral strains but is inactive against CXCR4 tropic HIV strains. CCR5-Δ32 is an allele of CCR5. An allele Δccr5 of the β-chemokine receptor gene CCR5 has been found to confer protection against HIV-1. In Europeans the prevalence of this allele is 5-14 per cent but is uncommon in Africans and Asians. This protective allele was found to be absent in majority of Indians. Its sporadic occurrence in southern and northern parts of India presume Caucasian admixture. The HIV R5 entry is prevented because of Δ32 deletion leading to a non-functional receptor. Homozygosity for this allele gives strong protection against HIV infection whereas the heterozygosity is associated with milder disease progression. However, genetic variations in the CCR5 gene have not been shown to affect virological response to MVC. On the other hand, MVC is substrate of CYP3A4 and P-gp; hence, dose adjustment is frequently required when co-administered with drugs that alter its pharmacokinetics. MVC is identified as substrate of the transport protein OATP1B1 and the variation 521T>C is linked with higher MVC plasma levels.
Thus, the only genetic test that is mandatory to perform before starting MVC treatment is the determination of viral tropism.4,99

**Conclusion and clinical relevance**

The objective of any therapy is to maximize the therapeutic outcome and to minimize the side effects. HAART represents very effective ART but is brought with innumerable side effects. The side effects like cutaneous hypersensitivity may be avoided with proper genetic testing which predisposes to susceptibility such as HLA-B*5701 associated ABC adverse reaction. Similarly, certain drugs like maraviroc may not be prescribed to HIV positive individuals with CCR5 tropic HIV. However, a large number of HAART drugs show change in pharmacokinetics due to variations in genes of drug metabolic pathway enzymes like CYP450, ATP binding cassette and UGTA1. Individualized approach to personalized HAART is influenced by host factors and is known as pharmacogenomics. It is also influenced by certain viral characteristics and the drug administered. Application of pharmacogenomics with understanding of medicine, viral characteristic of HIV is at the doorstep to guide the personalized prescription in which the right medication will be given to the right person. Several measures need to be taken for application of pharmacogenetic research in making a genetic test available for public. Many factors affect successful translation such as pharmacodynamics and pharmacokinetic properties of drug adversities, laboratory facilities, quality assurance and quality control (QA and QC) measures and type of tests.100 The reported associations have to undergo stringent validation in independent, ethnically diverse populations having highest number of HIV positive individuals.

**References**

1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. *Pharmacol Rev* 2011; 63 : 437-59.
2. Mahungu TW, Johnson MA, Owen A, Back DJ. The impact of pharmacogenetics on HIV therapy. *Int J STD AIDS* 2009; 20 : 145-51.
3. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics* 1998; 8 : 283-9.
4. Barco EÁ, Nóvoa SR. The pharmacogenetics of HIV treatment: A practical clinical approach. *J Pharmacogenomics Pharmacoproteomics* 2013; 4 : 116.
5. Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. *Pharmacogenet Genomics* 2012; 22 : 891-4.
6. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. *Mol Pharmacol* 2007; 71 : 619-27.
7. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, *et al*. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet* 2002; 359 : 727-32.
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet* 2002; 359: 1121-2.

Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K, Silva-Zolezzi I, Fernandez-Lopez JC, Jimenez-Sanchez G, et al. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. *Pharmacogenomics* 2011; 12: 809-14.

Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, Fux C, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. *J Infect Dis* 2008; 198: 864-7.

Rodriguez-Novoa S, Cuenca L, Morello J, Cordoba M, Blanco F, Jamenez-Nacher I, et al. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. *J Antimicrob Chemother* 2010; 65: 1567-9.

Galván CA, Elbarcha OC, Fernández EJ, Beltramo DM, Soria NW. Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir. *Clin Chim Acta* 2011; 412: 1382-4.

Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. *Clin Infect Dis* 2009; 48: e108-16.

Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABC2C gene haplotypes and tenofovir-induced proximal tubulopathy. *J Infect Dis* 2006; 194: 1481-91.

Kiser JJ, Aquilante CL, Anderson PL, King TM, Carter ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. *J Acquir Immune Defic Syndr* 2008; 47: 298-303.

Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, et al; Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. *Clin Infect Dis* 2006; 42: 401-7.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al; Swiss HIV Cohort Study. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. *Pharmacogenet Genomics* 2005; 15: 1-5.

Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. *AIDS* 2004; 18: 2391-400.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knecht H, Brockmeyer NH, et al. German Competence Network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. *J Antimicrob Chemother* 2008; 61: 914-8.

Rodriguez-Novoa S, Barreiro P, Rendón A, Jiménez-Nacher I, González-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. *Clin Infect Dis* 2005; 40: 1358-61.

Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motzinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group Study. *J Infect Dis* 2010; 202: 717-22.

Tsuiyia K, Gatamana H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, et al. Homozygous CYP2B6 *66 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz- containing regimens. *Biochem Biophys Res Commun* 2004; 319: 1322-6.

Klein K, Lang T, Sausselle T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. *Pharmacogenet Genomics* 2005; 15: 861-73.

Wang J, Sonnernborg A, Rane A, Josephson F, Lundgren S, Stähle L, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. *Pharmacogenomics* 2006; 16: 191-8.

Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, et al. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. *Ther Drug Monit* 2012; 34: 153-9.

Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al; Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet* 2002; 359: 30-6.

Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. *Eur J Med Res* 2003; 8: 531-4.

Sánchez A, Cabrera S, Santos D, Valverde MP, Fuertes A, Domínguez-Gil A, et al; Tormes Group. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. *Antimicrob Agents Chemother* 2011; 55: 5314-24.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, et al; German Competence Network for HIV/AIDS. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. *J Antimicrob Chemother* 2011; 66: 1332-9.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, et al; Nevirapine Toxicogenomics Study Team. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. *AIDS* 2011; 19: 1271-80.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. *Drug Metab Dispos* 1999; 27: 1488-95.
32. Ritchie MD, Haas DW, Motsinger AA, Donahue J, Erdem H, Raffanti S, et al. Drug transporter AA and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43 : 779-82.
33. Cicciacci C, Bargioli P, Ceccà S, Siriani E, Marazzi MC, Altan AM, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11 : 23-31.
34. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19 : 97-9.
35. Vitezica ZG, Milpid B, Lonjou C, Borot N, Ledger TN, Lefebvre A, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22 : 540-1.
36. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20 : 1621-6.
37. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Srikumpumaporn P, Manosuthi W, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009; 19 : 139-46.
38. D’silva S, Colah R, Ghosh K, Mukherjee MB. Prevalence of clinically relevant (TA)n UGT1A1 promoter alleles in Indian neonates. Curr Sci 2013; 105 : 446-7.
39. Colussi M, Colucci A, D’Avolio A, Baietto L, Gibbons S, Scandra M, Colucci D, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C–>T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 42 : 291-5.
40. Rodríguez Nóvoa S, Barreiro P, Rendón A, Barrios A, Corral A, Jiménez-Nacher I, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2008; 42 : 1225-5.
41. Álvarez E, Cuenca L, Morello J, Gurrero C, Vispo E, Corral A, et al. Polymorphisms in the ABCB1 gene (P-glycoprotein) influences raltegravir concentration. Proceedings of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2011 July 17-20; Rome, Italy. Abstract No. MDPE200.
42. Pesoa SA, Galván Bioch CA, Beltramo DM, Soria NW. Human immunodeficiency virus: pharmacogenetics of antiretroviral treatment. J Pharmacogenomics Pharmacoproteomics 2011; 6 : 002.
43. Maga G, Radi M, Gerard MA, Botta M, Ennifar E. HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate. Viruses 2010; 2 : 880-99.
44. Kallianpur A, Hulgán TP. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics 2009; 10 : 623-37.
45. [No authors listed]. 144-week data released on Gilead’s study 934 Comparing Truvada(R) to Combidv(R) Both in Combination with Sustiva. AIDS Patient Care STDS 2007; 21 : 603-4.
46. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354 : 251-60.
47. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 2010; 132 : 386-9.
48. Arribas JR, Pozniak AL, Gallant JE, Dejeus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47 : 74-8.
49. Abla N, Chin LW, Nakamura T, Liu L, Huang CC, Johns SJ, et al. The human multidrug resistance protein 4 (MRP4, ABCC4): Functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 2008; 325 : 859-68.
50. Anderson PL, Lamb J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42 : 441-9.
51. Kwaara A, Larrey M, Boamah I, Rezk NL, Olivier-Commey J, Erive E, et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 2009; 49 : 1079-90.
52. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential HIV infection. Drug 1996; 51 : 854-64.
53. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. Geneva: WHO; 2010.
54. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011; 71 : 659-71.
55. Hofmann C, Rockstoh JK. HIV 2012/2013. Medizin Fokus Verlag, Hamburg: 2012. Available from: https://hivbook.files.wordpress.com/2011/10/hivbook-2012.pdf, accessed on December 23, 2013.
56. Shankarkumar U, Shankarkumar A. HLA-B 17 prevalence in HIV-1 infected patients under antiretroviral treatment. Int J Hum Genet 2011; 11 : 59-62.
57. Miller M, Kahraman A, Ross B, Beste M, Gerken G. Evaluation of quantitative liver function tests in HIV-positive patients under antiretroviral therapy. Eur J Med Res 2009; 14 : 369-77.
60. Cluneck N, Mwamba C, Kabeya K, Matanda S, Vaira D, Ncoco C, et al. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting. *AIDS* 2014; 28 : 1143-53.

61. Miller V, Staszewski S, Boucher CA, Phair JP. Clinical experience with non-nucleoside reverse transcriptase inhibitors. *AIDS* 1997; II (Suppl A):5157-64.

62. Umapathy S, Pawar A, Bajpai S, Pazare AR, Ghosh K. HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients. *J Pharmocol Pharmacother* 2011; 2 : 114-5.

63. Sułkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. *Hepatology* 2002; 35 : 182-9.

64. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult Clinical Trials Group collaboration. *Clin Infect Dis* 2006; 43 : 783-6.

65. Marzolini C, Telenti A, Descostder LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. *AIDS* 2001; 15 : 71-5.

66. Gallego L, Barreiro P, del Rio R, González de Requena D, Rodriguez-Albaríno A, González-Lahoz J, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. *Clin Infect Dis* 2004; 38 : 430-2.

67. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. *Drugs* 2003; 63 : 2555-74.

68. Schroten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, et al; Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing high active antiretroviral treatment. *AIDS* 2001; 15 : 1019-23.

69. Dau B, Holodny M. The relationship between HIV infection and cardiovascular disease. *Curr Cardiol Rev* 2008; 4 : 203-18.

70. Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV+ protease inhibitor-related hyperlipidaemia. *Expert Opin Drug Saf* 2002; 1 : 5-17.

71. Barbaro G. Heart and HAART: Two sides of the coin for HIV-associated cardiology issues. *World J Cardiol* 2010; 2 : 53-7.

72. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. *J Pharmacol Exp Ther* 1996; 277 : 423-31.

73. Arnedo M, Taffé P, Sahli R, Furrr H, Hirschel B, Elzi L, et al; Swiss HIV Cohort Study. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. *Pharmacogenet Genom* 2007; 17 : 755-64.

74. Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, et al; SABAR Study Team. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. *AIDS* 2010; 24 : 885-90.

75. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, et al; ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. *HIV Clin Trials* 2010; II : 69-79.

76. Soriano V, Garcia-Gasco P, Vispo E, Ruiz-Sanchez A, Blanco F, Martin-Carbonero L, et al. Efficacy and safety of replacing ritonavir with atazanavir in HIV-infected patients with undetectable plasma viramia: final results of the SLOAT trial. *J Antimicrob Chemother* 2008; 61 : 200-5.

77. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrr H, Vernazza P, et al; Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. *J Infect Dis* 2005; 192 : 1381-6.

78. Choe P, Park W, Song J, Kim N, Song K, Park S. Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. *J Korean Med Sci* 2010; 25 : 1427-30.

79. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. *Proc Natl Acad Sci USA* 1997; 94 : 12128-32.

80. Rodriguez-Novo S, Martin-Carbonero L, Barreiro P, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. *AIDS* 2007; 21 : 41-6.

81. Reed B, Gitomer W. The genetics of stone disease. In: Stoller M, Meng MI, editors. *Urinary stone disease: The practical guide to medical and surgical management*. Totowa, New Jersey: Humana Press; 2007. p. 35-48.

82. Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. *Ear J Haematol* 2003; 70 : 410-2.

83. Nair V. HIV integrase as a target for antiviral chemotherapy. *Rev Med Virol* 2002; 12 : 179-93.

84. Hazuda DJ, Felock P, Wittmer M, Wolfe A, Stillmok C, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. *Science* 2000; 287 : 646-50.

85. Zembruski NC, Bächler G, Jö dicke L, Herzog M, Haefeli WE, Weiss J. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. *J Antimicrob Chemother* 2011; 66 : 802-12.

86. Minuesa G, Erkizia I, Arimany-Nardi C, Pastor-Anglada M, Ciotet B, Martinez-Picado J. The intracellular disposition of raltegravir is dependent on P-gp (*ABCB1*74). *Pharmacogenetics of once-daily raltegravir and atazanavir in healthy volunteers. *Antimicrob Agents Chemother* 2010; 54 : 4619-25.
89. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. *Pharmacotherapy* 2004; 24: 198-211.

90. Kuritzkes DR. HIV-1 entry inhibitors: an overview. *Curr Opin HIV AIDS* 2009; 4: 82-7.

91. Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B, *et al.* Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). *J Biol Chem* 2011; 286: 33409-21.

92. Majumder PP, Dey B. Absence of the HIV-1 protective Delta ccr5 allele in most ethnic populations of India. *Eur J Hum Genet* 2001; 9: 794-6.

93. Sabeti PC, Walsh E, Schaffner SF, Varilly P, Fry B, Hutcheson HB, *et al.* The case for selection at CCR5-Delta32. *PLoS Biol* 2005; 3: e378.

94. Guérin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, *et al.* SEROCO/HEMOCO Study. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. *AIDS* 2011; 14: 2788-90.

95. Tozzi V. Pharmacogenetics of antiretrovirals. *Antiviral Res* 2010; 85: 190-200.

96. Brumme ZL, Chan KJ, Dong W, Hogg R, O’Shaughnessy MV, Montaner JS, *et al.* CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. *AIDS* 2001; 15: 2259-66.

97. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. *Br J Clin Pharmacol* 2008; 65 (Suppl 1): 27-37.

98. Siccardi M, D’Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, *et al.* Maraviroc is a substrate for OATP1B1 *in vitro* and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. *Pharmacogenet Genomics* 2010; 20: 759-65.

99. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De luca A, *et al*; European Consensus Group on Clinical Management of Tropism Testing. European guidelines on the clinical management of HIV-1 tropism testing. *Lancet Infect Dis* 2011; 11: 394-407.

100. Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. *Pharmgenomics Pers Med* 2012; 5: 1-17.

*Reprint requests:* Dr Aruna Shankarkumar, Department of Transfusion Transmitted Disease, National Institute of Immunohaematology (ICMR), 13th floor, New Multistoreyed Building, KEM Hospital campus, Parel, Mumbai 400 012, Maharashtra, India
e-mail: arp21@rediffmail.com